Ikaria Inc.
This article was originally published in Start Up
Executive Summary
Ikaria is developing technology that triggers a natural hibernation-like mechanism that drastically lowers cells' metabolism and thus their need for oxygen. The company believes that inducing hibernation could buy time for blood-deprived tissues and minimize damage in cardiac surgery, strokes, heart attacks, and organ transplants.
You may also be interested in...
Ikaria’s Hybrid Business Model Taps Big Pharma Trends
Although Ikaria focuses on a highly specialized segment of the hospital market, its integrated business model offers insights into continuum of care strategies that pharma companies are evaluating in a reimbursement-focused world. The company’s promising strategy could get a boost from key trial read-outs as soon as late 2012.
Ikaria Backers Buy INO, Create Model for Self-Funding Discovery
Ikaria's private-equity funded acquisition of INO Therapeutics will allow the company to self-fund its continuing discovery programs while acting as a magnet for additional external commercial or clinical stage projects.
Ikaria Backers Buy INO, Create Model for Self-Funding Discovery
Ikaria's private-equity funded acquisition of INO Therapeutics will allow the company to self-fund its continuing discovery programs while acting as a magnet for additional external commercial or clinical stage projects.